Acute Respiratory Distress Syndrome Market will grow with 10.53% CAGR, Propelled by Rising Rate of Air Pollution and Lifestyle-related Diseases
22 Feb, 2023

According to Renub Research’s latest report “Acute Respiratory Distress Syndrome Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis” Acute Respiratory Distress Syndrome Market is estimated to reach US$ 1.83 Billion by 2028. Acute respiratory distress syndrome (ARDS) (chest X-ray) is a life-threatening condition of seriously ill patients, identified by poor oxygenation, pulmonary infiltrates, and acuity of onset. Sepsis syndrome with multiple organ failure remains the most common cause of death while respiratory failure causes a less percentage of deaths. Sepsis began in response to an infection. When sepsis is not recognized early and managed promptly, it can lead to septic shock, multiple organ failure, and, death.

In Sep 2020, According to the World Health Organisation (WHO), nearly half of the 49 million cases of sepsis once a year arise among children, resulting in 2.9 million deaths. Oxygen therapy is the main treatment for ARDS. This involves delivering extra oxygen to patients, through a mask, nasal cannula (two small tubes that enter the nose), or a tube inserted directly into the windpipe. Furthermore, enlarging incidents and frequency of acute lung injury, a broad range of risk factors for ARDS, and an increasing speed in a patient pool of covid-19 with ARDS act significantly drive the development of acute respiratory distress disorder. However, the high cost of devices, and lack of awareness about diseases, creates a major challenge for patients.

ARDS typically occurs in people who are already critically ill or who have significant injuries. It occurs when fluid fills up the air sacs in the lungs. ARDS is to improve oxygen levels and treat the underlying cause. Furthermore, Symptoms usually occur within a day or two of the original illness or trauma, and they may include extreme shortness of breath and gasping for air.

Usually, ARDS can affect persons of any age who suffer acute injury or illness affecting the lungs. The incidence increases with age, ranging from 16 affected individuals per 100,000 persons aged 15-19 to 306 affected individuals per 100,000 persons between the ages of 75 and 84. There is no difference in the incidence between males and females when ARDS is associated with sepsis and most other causes. However, the incidence is slightly higher among females when trauma is the underlying cause leading to ARDS.

In addition, the main medicine name is Methylprednisolone (Solu-Medrol) High-dose methylprednisolone has been used in trials of patients with ARDS who have persistent pulmonary infiltrates, fever, and high oxygen requirement despite resolution of pulmonary or extrapulmonary infection. However, to prevent or detect this condition seek help to quit, and avoid second-hand smoke whenever possible, get vaccinated every five years, which can reduce patients’ risk of lung infections and no drug has proved beneficial in the prevention or management of ARDS.

Diagnosis segment is expected to grow at a significant rate over the forecast period (2022-2028):

The Diagnosis segment is expected to grow at a significant rate. The diagnosis is based on the physical exam, chest X-ray, and oxygen levels. A laboratory test should include a complete blood count, chemistries, liver function tests, coagulation studies, and arterial blood gas (ABG) analysis. Some clinicians also measure D-dimer, troponin, and lactate levels to investigate common etiologies that can cause or mimic ARDS. It's also important to rule out other diseases and conditions, for example, certain heart problems that can produce similar symptoms. Additionally, the signs and symptoms of ARDS are similar to those of certain heart problems, do doctors may recommend heart tests such as Electrocardiogram and Echocardiogram.

Hospital Segment is expected to dominate the Market Share

The hospital segment is expected to dominate the market share. In Nov 2021, Hospital mortality was noted to be 35 percent among those with mild ARDS, 40 percent for those with moderate disease, and 46 percent for patients with severe ARDS according to Up To Date. ARDS is usually treated in the intensive care unit (ICU) along with treatment of the underlying cause.

Normally, Mechanical ventilation (a ventilator) is often used in caring for patients with ARDS. For milder cases of ARDS, oxygen may be given through a fitted face mask or a cannula fitted over the nose. The high market share can be attributed to factors like a rise in healthcare infrastructure, an increase in the cases of a number of patents, high quality of advanced ICU facilities, far favourable high quality of advanced ICU facilities, repayment policies in developed countries, a rising number of aging people worldwide payment policies in developed countries.

North America dominates the Acute Respiratory Distress Market:

North America dominates the market share because of increasing government support for Research & Development (R&D), well-advanced high technology, and the high cost of healthcare expenditure, and increasing incidence of acute lung injuries leading to acute respiratory distress syndrome is expected to dominate the market.

Competitive Landscape:

The market for Acute Respiratory Distress Syndrome is divided into: Silence Therapeutics plc. GILEAD SCIENCES INC, Terumo Corporation, GETINGE AB, Medtronic, Inc., FRESENIUS SE & CO. KGAA,   and NIPROPFIZER INC.

Market Summary:-

• Type:- The Report covers the Global Acute Respiratory Distress Disorder  Market, by type in 2 viewpoints (Diagnosis and treatment)
• End User: - Global Acute Respiratory Distress Syndrome breakup by the end user in 4 viewpoints (hospitals, specialty clinics, home healthcare, and others.
• Region: - Renub Research report covers region wise by market share in 5 viewpoints (North America, Europe, Asia-Pacific, South America and Middle East, and Africa.)

About Us
Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys, and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us
Renub Research
Phone: +1-478-202-3244 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research